Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Breast cancer

Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE

Nature Reviews Clinical Oncology volume 20, pages 662–663 (2023)Cite this article

Planning for a pregnancy in patients receiving adjuvant endocrine therapy following a diagnosis of hormone receptor (HR)-positive early stage breast cancer is challenging. Recent data from the POSITIVE trial provide reassuring prospective evidence that a temporary interruption of endocrine therapy for women with HR-positive breast cancer who are trying to conceive can be considered safe in the short term for selected patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Proposed decision-making algorithm for temporary interruption of adjuvant endocrine therapy in women with hormone receptor-positive breast cancer who wish to become pregnant.

References

  1. Vaz-Luis, I. et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann. Oncol. 33, 1119–1133 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Lambertini, M. et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann. Oncol. 31, 1664–1678 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Lambertini, M. et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J. Clin. Oncol. 39, 3293–3305 (2021).

    Article  PubMed  Google Scholar 

  4. Lambertini, M. et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J. Natl. Cancer Inst. 110, 426–429 (2018).

    Article  PubMed  Google Scholar 

  5. Anderson, R. A. et al. Survival after breast cancer in women with a subsequent live birth: influence of age at diagnosis and interval to subsequent pregnancy. Eur. J. Cancer 173, 113–122 (2022).

    Article  PubMed  Google Scholar 

  6. Khan, S. Z. et al. Knowledge, practice, and attitudes of physicians in low- and middle-income countries on fertility and pregnancy-related issues in young women with breast cancer. JCO Glob. Oncol. 8, e2100153 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sella, T. et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer 127, 2888–2894 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Partridge, A. H. et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N. Engl. J. Med. 388, 1645–1656 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Francis, P. A. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N. Engl. J. Med. 379, 122–137 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Arecco, L. et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum. Reprod. 37, 954–968 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

M.L. acknowledges the Italian Association for Cancer Research (‘Associazione Italiana per la Ricerca sul Cancro’, AIRC; MFAG 2020 ID 24698) for supporting his research in the field of breast cancer in young women and oncofertility.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy

    Luca Arecco & Matteo Lambertini

  2. Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Luca Arecco & Matteo Lambertini

Authors
  1. Luca Arecco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Lambertini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Lambertini.

Ethics declarations

Competing interests

M.L. has acted as an advisor of Astrazeneca, Exact Sciences, Gilead, Lilly, MSD, Novartis, Pfizer, Roche and Seagen, has received honoraria as a speaker from Daiichi Sankyo, Libbs, Lilly, Novartis, Pfizer, Roche, Sandoz and Takeda, has received travel grants and institutional research funding from Gilead. L.A. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arecco, L., Lambertini, M. Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE. Nat Rev Clin Oncol 20, 662–663 (2023). https://doi.org/10.1038/s41571-023-00797-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00797-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing